亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma

索拉非尼 医学 肝细胞癌 危险系数 内科学 实体瘤疗效评价标准 肝癌 肿瘤科 经导管动脉化疗栓塞 胃肠病学 随机对照试验 随机化 置信区间 肝功能 进行性疾病 化疗
作者
Masatoshi Kudo,Kazuomi Ueshima,Masafumi Ikeda,Takuji Torimura,Nobukazu Tanabe,Hiroshi Aikata,Namiki Izumi,Takahiro Yamasaki,Shunsuke Nojiri,Keisuke Hino,Hidetaka Tsumura,Teiji Kuzuya,Norio Isoda,Michihisa Moriguchi,Hajime Aino,Akio Ido,Naoto Kawabe,Kazuhiko Nakao,Yoshiyuki Wada,Sadahisa Ogasawara
出处
期刊:Liver cancer [Karger Publishers]
卷期号:11 (4): 354-367 被引量:141
标识
DOI:10.1159/000522547
摘要

Introduction: Several clinical trials comparing the efficacy and safety of transarterial chemoembolization (TACE) plus molecular-targeted agents versus TACE alone revealed no clinical benefits in progression-free survival (PFS) or overall survival (OS). Here, we report the final OS analysis from the TACTICS trial, which previously demonstrated significant improvement in PFS with TACE plus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) (NCT01217034). Methods: Patients with unresectable HCC were randomized to a TACE plus sorafenib group (N = 80) or a TACE alone group (N = 76). Patients in the combination treatment group received sorafenib 400 mg once daily for 2–3 weeks before TACE, followed by 800 mg once daily during on-demand conventional TACE sessions until time to untreatable progression. In this trial, TACE-specific PFS was used. TACE-specific PFS is defined as the time from randomization to progressive disease (PD) or death from any cause, and PD was defined as untreatable progression, caused by the inability of a patient to further receive or benefit from TACE for reasons that include intrahepatic tumor progression (25% increase vs. baseline) according to response evaluation criteria in cancer of the liver, the detection of extrahepatic spread, vascular invasion, or transient deterioration of liver function to Child-Pugh C after TACE. Results: At the cut-off date of July 31, 2020, 131 OS events were observed. The median OS was 36.2 months with TACE plus sorafenib and 30.8 months with TACE alone (hazard ratio [HR] = 0.861; 95% confidence interval [CI], 0.607–1.223; p = 0.40, ΔOS, 5.4 months). The updated PFS was 22.8 months with TACE plus sorafenib and 13.5 months with TACE alone (HR = 0.661; 95% CI, 0.466–0.938; p = 0.02). Post-trial treatments with active procedures/agents were received by 47 (58.8%) patients in the TACE plus sorafenib group and 58 (76.3%) in the TACE alone group (p = 0.01). In post hoc analysis, PFS and OS benefit were shown in HCC patients with tumor burden beyond up-to-7 criteria. Conclusions: In TACTICS trial, TACE plus sorafenib did not show significant OS benefit over TACE alone; however, clinical meaningful OS prolongation and significantly improved PFS was observed. Thus, the TACE plus sorafenib can be considered a choice of treatment in intermediate-stage HCC, especially in patients with high tumor burden. Trial Registration: NCT01217034.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
北极小熊完成签到,获得积分10
2秒前
3秒前
369ninja的应助被雪山大地采纳,获得10
6秒前
7秒前
8秒前
9秒前
12秒前
王佳佳发布了新的文献求助10
16秒前
华无剑的应助被雪山大地采纳,获得10
21秒前
栀鸢发布了新的文献求助30
24秒前
28秒前
28秒前
31秒前
高高的仇血完成签到,获得积分10
31秒前
cc发布了新的文献求助10
32秒前
casualplay发布了新的文献求助10
33秒前
木齐Jay完成签到,获得积分10
39秒前
华仔的应助被雪山大地采纳,获得10
40秒前
所所的应助被十四采纳,获得10
42秒前
隐形曼青的应助被lyw采纳,获得10
44秒前
aa完成签到,获得积分10
44秒前
obedVL完成签到,获得积分10
45秒前
xiaoping发布了新的文献求助10
51秒前
暮飘飘完成签到,获得积分20
54秒前
科研通AI6.4的应助被谨慎夏烟采纳,获得10
55秒前
55秒前
菌菌完成签到,获得积分10
56秒前
jj完成签到,获得积分10
1分钟前
1分钟前
醉熏的孤云完成签到,获得积分10
1分钟前
lyw发布了新的文献求助10
1分钟前
daomaihu完成签到,获得积分10
1分钟前
XNG完成签到,获得积分10
1分钟前
casualplay完成签到,获得积分10
1分钟前
GingerF的应助被Cherie77采纳,获得50
1分钟前
快乐的雁露完成签到,获得积分10
1分钟前
1分钟前
丘比特的应助被甜甜的悲采纳,获得10
1分钟前
嘻嘻哈哈的应助被科研通管家采纳,获得10
1分钟前
小蘑菇的应助被科研通管家采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165968
求助须知:如何正确求助?哪些是违规求助? 9559406
关于积分的说明 21750034
捐赠科研通 7756757
什么是DOI,文献DOI怎么找? 3429092
关于科研通互助平台的介绍 2553386
邀请新用户注册赠送积分活动 2473672